Salubris pharmaceuticals gets SAL0137 trial nod, controlling shareholder unpledges shares

Shenzhen Salubris Pharmaceuticals has received acceptance for the clinical trial application of SAL0137, an innovative oral small molecule drug for elevated lipoprotein(a) [Lp(a)], a risk factor for cardiovascular diseases. The company expects to proceed with clinical trials after a 60-day review period without objections. This drug aims to address unmet medical needs and expand Salubris Pharmaceuticals' product pipeline in chronic diseases.

Concurrently, controlling shareholder Hong Kong Salubris Pharmaceuticals unpledged 17,000,000 shares of Shenzhen Salubris Pharmaceuticals, representing 1.52% of the company's total share capital. This transaction reduces the total pledged shares held by the controlling shareholder to 97,000,000 shares, which constitutes 15.27% of its total holdings and 8.70% of the company's total share capital.

The unpledging of shares, completed on October 14, 2025, from pledges initiated in 2018 and 2019, indicates no changes to the company's actual control, operations, or governance. The company maintains good credit, and the pledge risk is deemed controllable.